PODOCYTE AS A POTENTIAL TARGET OF INFLAMMATION: ROLE OF PIOGLITAZONE HYDROCHLORIDE IN PATIENTS WITH TYPE 2 DIABETES
PODOCYTE AS A POTENTIAL TARGET OF INFLAMMATION: ROLE OF PIOGLITAZONE HYDROCHLORIDE IN PATIENTS WITH TYPE 2 DIABETES
复制标题
DOI：
10.4158/ep11378.or
复制
发表时间：
2012-07-01
影响因子：
4.2
通讯作者：
Chen, Yan
中科院分区：
文献类型：
--
作者：
Xing, Yan;Ye, Shandong;Chen, Yan
目的：观察盐酸吡格列酮对2型糖尿病患者尿沉渣足萼蛋白和单核细胞趋化蛋白1（MCP-1）排泄的影响，并探讨其治疗糖尿病的作用机制。方法：将98例既往接受二甲双胍、阿卡波糖或两者合用的2型糖尿病患者随机分为DP组（添加吡格列酮; n = 49）或DS组（添加磺酰脲类; n = 49）。治疗12周后，DP组加用磺脲类药物治疗（DS组）在空腹血糖和血红蛋白A（1c）方面表现出类似的改善，但只有DP组的收缩压和舒张压显著下降。此外，与DS组相比，DP组在减少尿MCP-1排泄方面表现出显著更好的功效。此外，尿白蛋白和尿沉渣足糖萼蛋白排泄量在DP组中显著降低，但在DS组中不显著。尿沉渣足糖萼蛋白/肌酐比值与尿白蛋白/肌酐比值呈正相关（r = 0.624; P
Objective: To observe the effects of pioglitazone hydrochloride on urinary sediment podocalyx in and monocyte chemoattractant protein-1 (MCP-1) excretion in patients with type 2 diabetes and to. explore its possible renoprotective mechanisms.Methods: Ninety-eight patients with uncontrolled type 2 diabetes, who were previously prescribed metformin, acarbose, or both, were randomly assigned to a DP group (add-on pioglitazone; n = 49) or a DS group (add-on sulfonylurea; n = 49).Results: After 12 weeks of treatment, both add-on pioglitazone therapy (the DP group) and add-on sulfonylurea therapy (the DS group) demonstrated a similar improvement in fasting blood glucose and hemoglobin A(1c), but systolic and diastolic blood pressure declined significantly in only the DP group. Moreover, the DP group showed significantly better efficacy in reducing urinary MCP-1 excretion in comparison with the DS group. Furthermore, both urinary albumin and urinary sediment podocalyxin excretion decreased significantly in the DP group but not in the DS group. The urinary sediment podocalyxin to creatinine ratio had a positive correlation with urinary albumin to creatinine ratio (r = 0.624; P